CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · Science & Nature

Anagliptin

chemical compound

Specimen drawers, botanical folios and brass scientific instruments under study light
Science and natureInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionJan 1, 2026
Entity authorityQ15269682 ↗
Source-derived summary

Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".

Research

A systematic review and meta-analysis of anagliptin, published in 2024, found that it is effective in lowering blood glucose in people with type 2 diabetes and that it may lower cholesterol.

Editorial summary

The public source identifies “Anagliptin” as chemical compound. This brief keeps that definition visible, then builds a research path around Anagliptin, chemical and compound.

Editorial reviewA practical orientation to terminology and classification, particularly when read beside dated observations, specimens or technical literature. The current lead gives the account dated anchors—2024—that can be checked directly. The selected authority fields contribute no independent date. Its value is orientation rather than verdict, with Anagliptin, chemical and compound providing the first useful test.
Editorial analysis

Why this record matters

A short description can identify a subject without explaining its stakes. For “Anagliptin”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.

Evidence profile

Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Jan 1, 2026. The linked authority identifier is Q15269682. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2024.

Critical limits

Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.

Best used for
  • Current terminology
  • Classification context
  • Finding cited technical literature
Verify next

Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.

Three-step research path

  1. Establish the record: confirm the title “Anagliptin”, its source revision and the description used here.
  2. Expand the search: follow Anagliptin primary sources, Anagliptin archive and Anagliptin research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Anagliptin”?
  2. Is the terminology current, historical or disputed?
  3. Has classification or technical consensus changed since the cited source?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Anagliptin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.